Home › Funds › Soleus Capital Management, L.P. › BMRN
Soleus Capital Management, L.P. position in BMRN
BIOMARIN PHARMACEUTICAL INC COM · Health Care
Soleus Capital Management, L.P. reported holding 375,572 shares of BMRN (BIOMARIN PHARMACEUTICAL INC COM) in its Q2 2026 13F filing — a position valued at US$21.5M, representing 0.74% of its reported portfolio and ranking #39 among its reported holdings. Soleus Capital Management, L.P. has disclosed BMRN holdings in 7 of the last 7 reported quarters, going back to Q4 2024.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How Soleus Capital Management, L.P.'s BMRN position evolved
Soleus Capital Management, L.P. first disclosed a stake in BMRN in Q4 2024 at 1,001,400 shares (US$65.8M). The position peaked in Q4 2025 at 1,320,000 shares, worth US$78.4M. Across 7 filings, Soleus Capital Management, L.P. increased the stake 2 time(s), trimmed it 4 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 375,572 shares valued at US$21.5M — a reduction of -275,000 shares quarter over quarter.. Notable position changes include a 48% increase in Q4 2025 (shares fell 5% over the following quarter), a 51% trim in Q1 2026 (shares rose 1% over the following quarter), a 42% trim in Q2 2026 (shares rose 5% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q4 2024 | 1.00M | $65.82M | New |
| Q1 2025 | 1.08M | $76.30M | Add |
| Q2 2025 | 902.30K | $49.60M | Reduce |
| Q3 2025 | 890.30K | $48.22M | Reduce |
| Q4 2025 | 1.32M | $78.45M | Add |
| Q1 2026 | 650.57K | $36.75M | Reduce |
| Q2 2026 | 375.57K | $21.49M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About BMRN and 13F data
BMRN (BIOMARIN PHARMACEUTICAL INC COM) is a Health Care company. 27 other funds we track also report a position in BMRN — the largest reported positions include PRIMECAP MANAGEMENT CO/CA/ (US$812.0M), Viking Global Investors (US$435.8M), VIKING GLOBAL INVESTORS LP (US$435.8M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding BMRN
- PRIMECAP MANAGEMENT CO/CA/ 14.19M sh · $811.96M · Q2 2026
- Viking Global Investors 7.62M sh · $435.82M · Q2 2026
- VIKING GLOBAL INVESTORS LP 7.62M sh · $435.82M · Q2 2026
- Vestal Point Capital, LP 6.03M sh · $344.75M · Q2 2026
- Deep Track Capital, LP 3.31M sh · $189.25M · Q2 2026
- TENOR CAPITAL MANAGEMENT Co., L.P. 111.50M sh · $108.89M · Q2 2026
More on Soleus Capital Management, L.P.
FAQ
How long has Soleus Capital Management, L.P. held BMRN?
Soleus Capital Management, L.P. has disclosed BMRN holdings in 7 of the last 7 reported quarters, going back to Q4 2024.
What is Soleus Capital Management, L.P.'s current position in BMRN?
As of Q2 2026, Soleus Capital Management, L.P. holds 375.57K shares of BMRN (BIOMARIN PHARMACEUTICAL INC COM), valued at $21.49M, representing 0.74% of its reported portfolio and ranking #39.
Has Soleus Capital Management, L.P. been buying or selling BMRN?
In the latest 13F filing (Q2 2026), Soleus Capital Management, L.P. reduced its position in BMRN. The position peaked in Q4 2025 at 1.32M shares.
Which other funds hold BMRN?
Other major institutional holders of BMRN include PRIMECAP MANAGEMENT CO/CA/, Viking Global Investors, VIKING GLOBAL INVESTORS LP, among 27 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.